home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9409d.zip
/
M9490606.TXT
< prev
next >
Wrap
Text File
|
1994-09-24
|
3KB
|
42 lines
Document 0606
DOCN M9490606
TI Motor analysis predicts progression in HIV-associated brain disease.
DT 9411
AU Arendt G; Hefter H; Hilperath F; von Giesen HJ; Strohmeyer G; Freund HJ;
Department of Neurology, Heinrich Heine University, Dusseldorf,;
Germany.
SO J Neurol Sci. 1994 May;123(1-2):180-5. Unique Identifier : AIDSLINE
MED/94342931
AB One hundred HIV-positive individuals without clinically evident central
nervous system (CNS) deficits entered this follow-up study and were
examined clinically and with a well-defined motor test battery every 3
months over 2 years or until they decreased. They underwent magnetic
resonance tomography once a year. None received any form of therapy at
onset of the study. Three groups were analyzed: (A) patients without
electrophysiologically detectable motor impairment (n = 23), (B)
patients with electrophysiologically detectable motor impairment but no
virostatic medication (n = 33), and (C) patients with motor deficits
undergoing AZT treatment (n = 44) after study onset. Group A patients,
although slightly deteriorating over time, had the best clinical and
electrophysiological outcome compared to the other groups, whereas group
B patients deteriorated markedly in both clinical and
electrophysiological tests, even though the majority did not develop
cerebral complications during the observation period. Those group C
patients belonging to early CDC stages (II and III) improved
electrophysiologically under AZT therapy, while 76% of the patients in
more advanced stages (CDC IVA-D) died of cerebral AIDS manifestations.
Four patients of this group, being alive at the end of the study, were
completely demented. It is suggested that early detectable motor
impairment predicts future cerebral involvement in AIDS. Late onset of
virostatic treatment did not influence the clinical outcome.
DE Adult AIDS Dementia Complex/*PHYSIOPATHOLOGY Comparative Study
Electrophysiology/METHODS Female Follow-Up Studies Human HIV
Seropositivity/DRUG THERAPY/*PHYSIOPATHOLOGY Magnetic Resonance Imaging
Male *Motor Activity *Neurologic Examination Predictive Value of
Tests Prognosis Time Factors Tremor Zidovudine/THERAPEUTIC USE
JOURNAL ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).